论文部分内容阅读
目的探讨紫杉醇联合顺铂不同给药途径治疗晚期卵巢癌的临床效果。方法将2010年10月—2014年1月130例晚期卵巢患者随机分成观察组和对照组各65例,对照组患者首先静脉滴注135 mg/m2紫杉醇,24 h后静脉滴注75 mg/m2顺铂。观察组首先静脉滴注135 mg/m2紫杉醇,24 h后腹腔灌注60 mg/m2顺铂,7 d后再腹腔灌注60 mg/m2紫杉醇。腹腔灌注前抽尽腹水,随后将药物加入1 000 ml温生理盐水中行腹腔灌注,为使药物能够均匀分布于腹腔中,灌注过程中嘱患者每隔30 min变换一下体位。两组均是3周1个疗程,共治疗6个疗程。比较两组疗效及不良反应。计数资料采用χ2检验,P<0.05为差异有统计学意义。结果观察组总有效率64.62%,对照组41.54%,两组比较差异有统计学意义(χ2=6.949,P<0.05);观察组疾病控制率86.15,对照组64.62%,两组比较差异有统计学意义(χ2=8.125,P<0.05);观察组中性粒细胞降低、血红蛋白降低、恶心呕吐、肝功能受损、关节肌肉痛发生率分别为76.92%、56.92%、55.38%、18.46%、33.85%明显高于对照组的60.00%、36.92%、33.85%、21.54%、18.46%(χ2=4.311、5.220、6.102、5.535、3.983,均P<0.05)。结论应用腹腔灌注方式进行紫杉醇联合顺铂给药对晚期卵巢癌的治疗有着突出的疗效,但易引发不良反应,因而在为晚期卵巢癌实行综合治疗时应进一步探明其价值。
Objective To investigate the clinical effect of paclitaxel combined with cisplatin on the treatment of advanced ovarian cancer by different routes of administration. Methods A total of 130 patients with advanced ovarian disease from October 2010 to January 2014 were randomly divided into observation group (65 cases) and control group (65 cases). In the control group, intravenous infusion of paclitaxel (135 mg / Cisplatin. The observation group received intravenous infusion of paclitaxel (135 mg / m2) and cisplatin (60 mg / m2) intraperitoneally 24 h later. Paclitaxel (60 mg / m2) was intraperitoneally injected 7 days later. Peritoneal perfusion prior to pumping ascites, and then the drug was added to 1000 ml of warm saline intraperitoneal perfusion, in order to enable the drug to be evenly distributed in the abdominal cavity, Zhu Zhu during the infusion process every 30 minutes change position. Both groups are 3 weeks a course of treatment, a total of 6 courses of treatment. The curative effect and adverse reaction of two groups were compared. Count data using χ2 test, P <0.05 for the difference was statistically significant. Results The total effective rate was 64.62% in the observation group and 41.54% in the control group, with significant difference between the two groups (χ2 = 6.949, P <0.05). The disease control rate in the observation group was 86.15% and that in the control group was 64.62% (Χ2 = 8.125, P <0.05). The incidences of neutropenia, hemoglobin, nausea and vomiting, impaired liver function and joint muscle pain in the observation group were 76.92%, 56.92%, 55.38% and 18.46% 33.85% were significantly higher than 60.00%, 36.92%, 33.85%, 21.54%, 18.46% of the control group (χ2 = 4.311,5.220,6.102,5.535,3.983, all P <0.05). Conclusion Intraperitoneal injection of paclitaxel combined with cisplatin has a remarkable curative effect on the treatment of advanced ovarian cancer, but it is easy to cause adverse reactions. Therefore, the value of paclitaxel plus cisplatin should be further ascertained in the treatment of advanced ovarian cancer.